Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma-Reference-Cited by-同舟云学术

Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma

Published:2019-08-19 Issue: Volume:9 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Cao Yaqing,Lu Wenyi,Sun Rui,Jin Xin,Cheng Lin,He Xiaoyuan,Wang Luqiao,Yuan Ting,Lyu Cuicui,Zhao Mingfeng

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference21 articles.

1. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma;Neelapu;N Engl J Med,2017

2. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study;Crump;Blood,2017

3. Chimeric antigen receptor T-cell therapies for lymphoma;Brudno;Nat Rev Clin Oncol,2018

4. Incorporation of immune checkpoint blockade into chimeric antigen receptor T cells (CAR-Ts): combination or built-in CAR-T;Yoon;Int J Mol Sci,2018

5. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells;Rupp;Sci Rep,2017

Cited by 105 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunomodulatory signalling networks in glioblastoma multiforme: a comprehensive review of therapeutic approaches;Human Cell;2024-07-31

2. CAR-T cell combination therapies in hematologic malignancies;Experimental Hematology & Oncology;2024-07-18

3. Fueling CARs: metabolic strategies to enhance CAR T-cell therapy;Experimental Hematology & Oncology;2024-07-10

4. Strategies to reprogram anti-inflammatory macrophages towards pro-inflammatory macrophages to support cancer immunotherapies;Immunology Letters;2024-06

5. CRISPR/Cas-based CAR-T cells: production and application;Biomarker Research;2024-05-31